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Abstract  
Introduction: Poor retention of patients in care is a major driver of poor performance and increased morbidity and mortality in HIV/AIDS 
programme despite the expansion and advancement Anti-retroviral Therapy (ART). The objective of this study is to assess retention rates and 
possible determining factors in People Living with HIV (PLHIV) on ART. Methods: This is a descriptive, cross-sectional study conducted in Federal 
Medical Center, Ido-Ekiti, Nigeria. Medical records of clients who were enrolled in ART Care and support unit (HIV Clinic) of the health facility from 
2005 to 2012 were reviewed and analyzed using SPSS version 16. A total of 621 client records were reviewed for basic demographic information, 
CD4 count, WHO stage, number of follow-up visit, client ART status and client retention status (defined as client attending at least one clinic visit in 
2012. Results: A total of 347(63%) patients were retained in care and 208(37%) were not retained over the seven year review period. Retention 
was statistically significant with age (P-value 0.031), ART status (P-value 0.000) baseline CD4 (P-value 0.004), year of diagnosis and ART initiation 
(P-value= 0.027). Poor retention was associated decreasing age, pre-ART client, HIV stage 1&IV client and baseline CD4 above 400cell/mm3. 
Conclusion: Retention in care of PLHIV is a minimum necessary condition for maintaining or restoring health in the long run. The strategies to 
sustain and improve retention rate should be adopted to maximize ART benefits. A follow-up study on other factors affecting retention from 
diagnosis to long term retention ART programme is recommended.  
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For Human Immuno-deficiency Virus (HIV)-infected patients, 
retention in care is a minimum necessary condition for maintaining 
or restoring health. Of the 33 million persons living with Human 
Immuno-deficiency Virus/Acquired Immune Deficiency Virus 
(HIV/AIDS), 23 million reside in sub-Saharan Africa, nearly 5 million 
in Asia, and 1.6 million in Latin America and the Caribbean. This 
implies that the burden of HIV infection is highest in sub-Saharan 
Africa. The remarkable expansion of access to ART for HIV/AIDS in 
resource-constrained countries has given about seven million HIV-
positive adults in sub-Saharan Africa the opportunity to achieve 
what for many may be nearly normal life expectancies [1]. Despite 
significant success in scaling up ART programmes worldwide, many 
people living with HIV (PLHIV) start ART late in the progression of 
HIV infection, resulting in high rates of early mortality on ART [2]. 
The majority of PLHIV remain undiagnosed and many do not access 
HIV care and treatment despite a positive test. They are lost at 
every step along the continuum of care, particularly in the period 
between HIV diagnosis and initiation of ART. It is now recognized 
that poor retention of patients in care, especially in the pre-ART 
period is a major driver of poor performance and increased 
morbidity and mortality in HIV/AIDS programme [2]. Retention in 
HIV care can be defined as continuous engagement from the time 
of diagnosis in a package of prevention, treatment, support and 
care services. It is defined from the moment of initial engagement 
in care, when a person with HIV is linked successfully to services, to 
assessment for eligibility, initiation on ART and retention in lifelong 
ART care [3]. Retention in HIV care is also the ability to adhere to 
critical aspects of care, attend regular follow-up appointments, 
scheduled lab tests, and other monitoring activities, according to 
health system standards and as prescribed by a health care provider 
[4]. Retention is critical to reduce HIV-related morbidity and 
mortality, reduce the incidence of new infections in children and 
adults, and reduce development of ART resistance. Different schools 
of thought have defined retention in care in terms of number of 
clinical visit at given time frame. Three studies published in 2002 
measured patient retention rates by using roughly the same 
definition of 1 medical visit every 6 months over a 2-year period [5-
7]. A wide range was found in the retention rates (18%-61%). 
Another study done in Nigeria, measured patient retention as having 
one or more clinic visits in the review year [8].  
  
Retention in care has been highlighted as an important element of 
clinical success for the patient and the program. Whereas attending 
clinical appointments is associated with favorable patient outcomes 
among individuals with HIV on ART [9,10]. Poor retention in care 
has been associated with higher mortality for both ART and pre-ART 
patients in both high-income and resource-limited settings [11-13]. 
A study from Kenya found that patients not retained in care are 
generally sicker than those who are retained in care and may 
therefore experience poorer long-term outcomes [14]. In addition to 
retrieving medication, clinical follow-up visits are crucial for 
monitoring drug toxicity, clinical HIV progression, and to diagnose 
and treat new opportunistic infections (OIs) and other concurrent 
diseases that may occur [4]. Identifying patients who are not 
retained in care can be challenging as poor retention can include a 
range of behaviors such as missing a single scheduled clinical visit 
to lost-to-follow-up (LTFU), a term use to describe patients who fail 
to present to clinic for a certain period of time and are not known to 
have died [13]. Although overall treatment adherence among sub-
Sahara African patients has been high, recent evidence suggests 
that a large number of PLHIV in the region who have started in 
treatment programs are not retained in care. A review of 33 patient 
cohorts taking ART in 13 African countries suggested only 60 
percent of patients remain enrolled in programs after two years, 
with LTFU accounting for 56 percent of all attrition [13]. 
Furthermore, a study conducted in Uganda found that over 25 
percent of patients eligible for ART did not complete screening or 
begin treatment [11]. The potentially high attrition rates suggest the 
need for a better understanding of how PLHIV integrate ART and 
care seeking behavior in the context of their daily lives to support 
adherence to treatment and program retention.  
  
The proportion of adult patients retained between any two points 
from testing positive for HIV to initiating ART in sub-Saharan African 
HIV/AIDS care programs were categorized in 3 stages; Stage 1 
(from HIV testing to receipt of CD4 count results or clinical staging), 
Stage 2 (from clinical staging to ART eligibility) an Stage 3 (from 
ART eligibility to ART initiation). The range reported for the 
proportions of patients retained in Stage 1 was 35%-88% and a 
median range of 59%. For Stage 2 the range was 31%-95% with a 
median range of 46%. While for Stage 3 the range was 14%-84% 
and the median range 68% [15]. One key reason for the poor 
retention of pre-ART clients in care is persistence of low starting 
CD4 counts for ART eligibility which results in failure of linking HIV 
positive clients from HIV testing (stage 1) to HIV care and retention 
in care. As most patients are asymptomatic during the pre-ART 
period, they may not perceive themselves as requiring medical care 
hence lack understanding in the importance of enrolling in care. 
Other reasons for poor retention include issues of disclosure like 
fear being recognized as a client of an HIV clinic. Issues of 
stigmatization and discrimination that could result in job lost. Patient 
mobility due to factors like severe illness, distance to clinic, lack of 
transportation and Poverty [16,17]. Those presented with low CD4 
count are likely to have died before reaching stage of ART. Some 
health facility factors that affect retention include poor attitude of 
health workers, lack of good organization. Long waiting time at 
facilities may also be a factors contributing to low retention rates 
[11,18,19]. Although some estimates suggest that retention in care 
is poor in Africa; around 50% to 70% at 2 years after ART initiation 
-these estimates rely on studies that consider patients as retained in 
care only when they are retained in a particular clinic; this is an 
unrealistic expectation in a decentralized system and in regions 
where people frequently relocate to maintain a livelihood. Studies 
that attempt to account for patients as they move across the 
network of care suggest retention rates are considerably higher, up 
to 85%-90% at 2 years [20,21]. This study was conducted to assess 
retention rates and possible determining factors in PLHIV on ART in 
the care and support unit of Federal Medical Centre, Ido-Ekiti, Ekiti 





This is a descriptive cross-sectional study, conducted in Federal 
Medical Center (FMC), Ido-Ekiti which is one of the two tertiary 
health institutions in Ekiti state, South-west, Nigeria. The primary 
data were obtained from medical records of clients who were 
enrolled in ART Care and support unit (HIV Clinic) of the health 
facility from 2005 to 2012.The care and support unit was 
commenced in 2005 as integration of normal hospital care and 
metamorphosed into a full fleshed HIV programme in 2010. Basic 
demographic information, CD4 count, WHO stage, number of follow-
up visit, client ART status and client retention status (defined as 
client attending at least one clinic visit in year 2012) were reviewed 
and analyzed. A total of 621 client records were reviewed and 
entered into a performer, then into a computer software SPSS 
version 16.0. All persons tested positive to HIV but not enrolled 
were excluded from the study. Patients that died before year of 
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review were not considered for retention. Client outcomes in care 
were assessed as "in care", "loss to follow-up" "discontinued care" 
and "died". SPSS version 16.0 was used to analyses the data. A 
trend analysis of clinical and outcome data as well as their 
association with treatment outcomes were done. Chi-square test 
was used determining factors associated with retention. A p-value of 
less than 0.05 was considered as statistically significant. Ethical 
approval for the study was obtained from the ethical and review 
committee of Federal Medical Centre, Ido-Ekiti. The limitation of this 
study was that for patient who did not give valid address or phone 
contact, determining their retention status in terms of whether 





The study population included 621 patients; 426(68.6%) were 
female and 195 (31%) were males (Table 1) The mean age at time 
of enrollment was 36. 33 ± 13.12years. With age 26 to 49 
accounting for over two-third (71.2%) of patients as seen in Table 
1. A larger percentage patient 65.5% were diagnosed from 2009 to 
2011 and 64.2% initiating ART within the same year (Table 2). 
During the period of study, a total of 531(87%) were on ART while 
80 (12.9%) had not initiated ART. At initiation of ART, 54.3% of the 
patients had CD4 ≤200 cells/mm3. Three hundred and fifty two 
patients (56.7%) at diagnosis were in WHO stage 3 and 4. One 
hundred and nine (17.6%) in stage 2, while 160(25.8 %) in stage 1. 
In the year of review 2012, a total of 274(44.1%) patient had zero 
clinic attendance, 191(30.8%) attended clinic between 1-4 times. 
While, 156(25.1%) had greater than 5 clinic visits. Figure 1 shows 
the retention status of patient; a total of 347 (63%) were retained 
while 208(37%) where not retained over a seven year period 
(Figure 2)(Table 3). The rate of retention per year was highest in 
the first year 2005 with five enrollees and with all of them retained 
that year followed by 2010 and 2006 with rates of 73 and 72.3 
percent respectively. In 2008 and 2011 retention rate were below 
average with 48.4 and 49.7 percent respectively. Table 4 shows 
the factors affecting retention. There is statistically significant 
association between age and retention status (P-value of 0.031). 
Retention increased with age; it was lowest in age ≤15 years 
(42.9%) and highest in age ≤50 years (65. 3%). Sex was not 
statistically significant with retention (P- value of 0.307). ART status 
showed a strong association with retention (P-value of 0.000). More 
than two- third (67.3%) of PLHIV on ART were retained, while only 
20.3% of those not on ART were retained. The CD4 count at 
diagnosis with P- value of 0.004 was statistically significant with 
higher retention on patient with CD4 bellow 400 and lower in those 
with CD4 above 400. The retention rate was 72.8% from 2005 to 
2007, 57.5% from 2008 to 2009 and 61.5% from 2010 to 2011. 
Therefore the year of diagnosis was statistically significant with rate 
of retention at a P-value of 0.027. Year of initiation on ART was also 
statistically significant as the year of diagnosis with similar P-value 
of 0.027(Table 5). There was no statistically significant association 
between level of retention with age, sex, ART status, CD4 count, 
WHO staging at diagnosis, year of diagnosis and year of ART 





Retention in long-term HIV care both before and after the initiation 
of ART is important not only to reduce individual HIV-related 
mortality and morbidity but also as a means to deliver "positive 
prevention" interventions aimed at reducing ongoing transmission, 
In this seven years study of retention among HIV patient in a 
tertiary health institution, south-west Nigeria, approximately only 3 
in 5 (63%) patients were retained while 37% were not retained 
between March 2005 and December 2012. Among those retained, 
335(67.5%) patient were on ART while only 12(20.3%) were Pre-
ART patient, after eliminating those who died or whose records 
could not be found, from the study. This was very similar to findings 
from other HIV treatment programme; Ugoji et al. [8] which 
showed 62.4% retention; out of which 75.8% of patients were on 
ART, and 23.4% were not on ART. Studies from 2007-2009 from 
across Africa, estimated a median retention in care for 12 months 
after treatment initiation to be 79.4%, with a range of 55-93% [2]. 
In a meta-analysis of the pre-ART attrition in Sub-Saharan Africa 
[22], the attrition in Stage 1 was 22.4% and the attrition in Stage 3 
was 37.1%. In a single site cohort study in South Africa [23], the 
cumulative retention in care of ART eligible patients from HIV 
diagnosis to 6-12 months after ART initiation was 36.9%. Although 
these studies differ in some of the stage definitions and follow-up 
periods, the rates of attrition are similar to our study, suggesting 
comparable rates of attrition in Sub-Saharan Africa and India. The 
poor retention rate in pre-ART patient is due to CD4 count greater 
than 350 cell/mm3 and absence of illness that would have 
warranted their visiting the hospital. Lessells et al., in their study in 
South Africa showed that the increase ART initiation to 350cell/mm3 
in 2010 guide line, improved retention rates [23]. In our analysis, 
increased risk of LTFU or poor retention was associated with age, 
CD4 level at ART initiation, ART status, year of diagnosis and year of 
initiation of ART. Younger age was associated with poor retention. 
In this study, retention increased with age; it was lowest in age ≤15 
years (42.9%) and highest in age ≤50 years (65. 3%). Similarly two 
studies in 2011 and 2012, by Indian National AIDS Control 
Organization [22,24], showed that younger adults fail to access 
health services efficiently. Studies by Lessells et al., Forster et al., 
Bassett et al., Bateganya et al., Wanyenze et al. and Helleringer et 
al. were also consistent with findings [23,25-29]. The WHO report 
on retention in 2011 stated that, diagnosing and retaining HIV-
exposed and infected children and adolescents in care present 
unique challenges [1]. Their vulnerability is heightened by 
dependence upon a caregiver. The CD4 count was statistically 
significant in our study with P-value of 0.004. There was high 
retention rate in patient with baseline CD4 bellow 400cell/mm3 while 
those with baseline CD4 greater than 400cell/mm3 had poor 
retention rate. This was consistent with studies by Lessells et al. and 
Charurat et al. [23,30]. Although retention was lowest in baseline 
CD4 < 100cells/mm3 and > 350cell/mm3 in study by Charurat et al, 
it was a high (66.9%) in patient with CD4 less than 100cell/mm3 in 
our study. However in a study by Alvarez-Uria et al, there was no 
significant association between baselines CD4 cell counts above 
350cell/mm3 with poor retention [31].  
  
Retention rates decreased with years of enrollment because more 
people live the programme from reasons of death, change in 
location, feeling of wellness after vial load have been suppressed, 
improved conditions of health or other economic and religious 
factors, especially in Africa. According to data presented by 
Stevenson at a Conference on Retroviruses and Opportunistic 
Infections (CROI) in Seattle, aggregate six-month non-retention 
rates were 21 percent in 2005 and 2010, and there was no 
significant difference in the 12 month non-retention rates in 2005 or 
2010 - which were 27 and 29 percent respectively [32]. However 
Cote d'Ivoire, Nigeria and Rwanda had increased non-retention 
rates during this period. There was no significant association 
between retention with gender and WHO staging at diagnosis. 
Although in this study female patient were about two-third (68.6%) 
of study subject and had slightly marginal retention rate than men, 
there was no statistically significantly associated between male or 
female (P- value 0.309 (>0.05)). In many other study reviewed 
there was higher probability for women to be retain in HIV 
programmes than men [13,30, 33,34].The finding that higher 
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proportion of women initiated on ART remained in follow-up, may 
reflect gender-differences in health-seeking behaviors which has 
been shown to affect retention in care in other resource-limited 
countries [35,36]. WHO staging was not a significant risk factor to 
the retention rate in our study, with a P-value of 0.129(>0.05), 
retention was highest in patient with WHO stage 2 (72 %) than 
stages 1, 3, 4 with marginal difference of 1.8%. However the study 
by Ugoji et al. showed a strong association between retention and 
WHO staging as retention decreased with higher baseline WHO 
stage [8]. There was no statistical significant difference between the 
levels of retention in those retained with factors like age, sex, ART 
status, CD4 count WHO staging at diagnoses and year of diagnosis 





Retention in care of PLHIV is a minimum necessary condition for 
maintaining or restoring health in the long run. With the scaling of 
ART programme and the expansion of PLHIV on medication 
especially in low and middle income countries, drastic measures and 
strategy should be deployed to address the issue of long term 
retention in care. This is to maximize the gains and sustain progress 
already made, halt and reverse HIV/AIDS pandemic in line with 
achieving MDG goal 6. The predictors of long time retention in HIV 
programmes are age, ART status, and baseline CD4 count, year of 
diagnosis and year of ART initiation. This also corresponds to 
findings in many other studies reviewed, with varying methods and 
design. Though our study was limited by the challenges of missing 
records and difficulty in tracing whether some of the patients were 
dead, transferred out, discontinued care or actually loss to follow-
up. We recommend that quality data management in HIV 
programmes in health facility should be strengthen to improve 
results from researches that will improve the strategies and 
procedures to boost long term retention. A follow-up analytical or 
experimental study will be conducted to highlight other factors 
associated long term retention from HIV testing to linkage in care 
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Table 1: year of diagnosis, art initiation and socio- demographic characteristics of HIV 
clients 
            Variable N = 621 
Frequency Percentage 
Age Group (in years)       
  <  15 43 6.9 
  15 – 19 2 0.3 
  20 – 25 43 6.9 
  26 – 49 442 71.2 
  ≥ 50 91 14.7 
  Mean = 36.33±13.123 
Sex       
  Female 426 68.6 
  Male 195 31.4 
Year of Diagnosis       
  2005 – 2006 34 5.5 
  2007 - 2008 180 29.0 
  2009 – 2011 407 65.5 
Year of ART Initiation       
  2005 – 2006 31 5.7 
  2007 – 2008 163 30.1 




Table 2: WHO staging and clinic attendance of HIV clients  
Variable N = 621 
Frequency Percentage 
ART Status       
  Yes 541 87.1 
  No 80 12.9 
CD4 Count       
  ≤ 100 196 31.6 
  101 – 200 141 22.7 
  201 – 300 99 15.9 
  301 – 400 74 11.9 
  >400 111 17.9 
WHO Stage at Diagnosis       
  1 160 25.8 
  2 109 17.6 
  3 185 29.8 
  4 167 26.9 
Number of Clinic Days 
Attended 
      
  0 274 44.1 
  1 – 4 191 30.8 
  ≥5 156 25.1 
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Table 3: percentage of patients retained per year 
Year   Number Enrolled Number Retained in 2012 Percentage Retention 
2005 5 5 100.0 
2006 29 21 72.4 
2007 89 57 64.1 
2008 91 44 48.4 
2009 102 60 58.8 
2010 124 75 73.5 
2011 181 90 49.7 




Table 4:  factors affecting retention rate 
  Retention X2 p – value 
    Yes No 
Age <15 18 (42.9) 24 (57.1) 10.672 0.031 
  15 – 19 1 (50.0) 1 (50.0)     
  20 - 25 20 (51.3) 19 (48.7)     
  26 – 49 259 (65.2) 138 (34.8)     
  ≥50 49 (65.3) 26 (34.7)     
Sex       1.044 0.307 
  Female 243 (63.9) 137 (36.1)     
  Male 104 (59.4) 71 (40.6)     
ART Status       50.135 0.000 
  Yes 335 (67.5) 161 (32.5)     
  No 12 (20.3) 47 (79.7)     
CD4 Count       15.500 0.004 
  ≤100 101 (66.9) 50 (33.10     
  101 – 200 75 (59.5) 51 (40.5)     
  201 – 300 69 (72.6) 26 (38.1)     
  301 – 400 48 (66.7) 24 (33.3)     
  >400 54 (48.6) 57 (51.4)     
WHO Stage at 
Diagnosis 
      5.666 0.129 
  1 94 (59.1) 65 (40.9)     
  2 76 (72.4) 29 (27.6)     
  3 99 (61.9) 61 (38.1)     
  4 78 (59.5) 53 (40.5)     
Year of Diagnosis       7.234 0.027 
  2005 – 2007 83 (72.8) 31 (27.2)     
  2008 – 2009 104   (57.5) 77 (42.5)     
  2010 – 2011 160 (61.5) 100 (38.5)     
Year of Initiation       7.234 0.027 
  2005 – 2007 83 (72.8) 31 (27.2)     
  2008 – 2009 104   (57.5) 77 (42.5)     
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Table 5: level of retention among clients 
  Level of Retention X2 p – value 
    1 – 4 ≥5 
Age <15 14 (77.8) 4 (22.2) 4.852 0.303 
  15 – 19 1 (100.0) 0 (0.0)     
  20 – 25 11 (55.0) 9 (45.0)     
  26 – 49 139 (53.7) 120 (46.3)     
  ≥50         
Sex       4.852 0.303 
  Female 136 (56.0) 107 (44.0)     
  Male 55 (52.9) 49 (47.1)     
ART Status       0.054 0.816 
  Yes 184 (54.9) 151 (45.1)     
  No         
CD4 Count       3.223 0.521 
  ≤100 55 (54.5) 46 (45.5)     
  101 – 200 46 (61.3) 29 (38.7)     
  201 – 300 33 (47.8) 36 (552.2)     
  301 – 400 25 (52.1) 23 (47.9)     
  >400 32 (59.3) 32 (40.7)     
WHO Stage of Diagnosis       2.462 0.482 
  1 
  
57 (60.6) 37 (39.4)     
  2 42 (55.3) 34 (44.7)     
  3 54 (54.5) 45 (45.50     
  4 38 (48.7) 40 (51.3)     
Year of Diagnosis       2.340 0.310 
  2005 – 2007 14 (53.8) 12 (46.2)     
  2008 – 2009 62 (61.4) 39 (38.6)     
  2010 – 2011 115 (52.3) 105 (47.7)     
Year of Initiation       2.340 0.310 
  2005 – 2007 14 (53.8) 12 (46.2)     
  2008 – 2009 62 (61.4) 39 (38.6)     
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Figure 2: Number of clinic days among the retained clients 
 
 
 
 
 
 
 
